ALACHUA, Fla., March 13 /PRNewswire-FirstCall/ -- Tutogen Medical, Inc. , a leading manufacturer of sterile biological implant products made from human (allograft) and animal (xenograft) tissue, today announced that Mr. Guy L. Mayer, Chief Executive Officer of Tutogen, has been contacted by representatives of Zimmer Holdings, Inc. to enter into discussions on a range of potential strategic transactions, which could possibly include further investment by Zimmer in securities of Tutogen Medical or the acquisition by Zimmer of some or all of the outstanding common stock of Tutogen.
Zimmer Holdings, Inc. filed Schedule 13 D/A on Friday, March 10, 2006 expressing its intention to initiate discussions with Tutogen Medical, Inc.
Guy L. Mayer, president and CEO of Tutogen Medical, said, "We have made a great deal of progress in the past year in positioning the Company for improved performance. We believe this approach by Zimmer is indicative of that progress. We look forward to considering any and all strategic options that will help us to expand the reach of our products worldwide and that will appropriately enhance value for our loyal shareholders."
About Tutogen Medical, Inc.
Tutogen Medical, Inc. manufactures sterile biological implant products made from human (allograft) and animal (xenograft) tissue. Tutogen utilizes its Tutoplast Process(R) of tissue preservation and viral inactivation to manufacture and deliver sterile bio-implants used in spinal/trauma, urology, dental, ophthalmology, and general surgery procedures. The Company's Tutoplast(R) products are sold and distributed worldwide by Zimmer Spine and Zimmer Dental, subsidiaries of Zimmer Holdings, Inc. the Mentor Corporation, IOP, Inc. and through independent distributors and subsidiaries in the U.S. and other international markets. For more information, visit the Company's Web site at http://www.tutogen.com .
Forward-Looking Statement Disclaimer: Certain statements in this news release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, which may differ materially from those set forth in these statements. In addition, the economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission could affect such results.
Contacts: Bob Johnston Chief Financial Officer Lytham Partners, LLC Tutogen Medical, Inc. Institutional: Joe Diaz 386-462-0402 ext. 109 Retail: Joe Dorame bjohnston@tutogen.com 602-889-9700
Tutogen Medical, Inc.CONTACT: Bob Johnston, Chief Financial Officer of Tutogen Medical, Inc.,+1-386-462-0402, ext. 109, bjohnston@tutogen.com; or Institutional, JoeDiaz, or Retail, Joe Dorame, both of Lytham Partners, LLC, +1-602-889-9700,for Tutogen Medical, Inc.
Web site: http://www.tutogen.com/
